Phagos

Phagos develops bacteriophage therapies as a sustainable alternative to antibiotics, combining microbiology with artificial intelligence to create personalized bacterial treatments. The company uses patented technology to produce large-scale, customized phage-based veterinary medicines and plans to extend the approach to human health. Its mission is to end bacterial disease by using phages, the natural predators of bacteria, to address antibiotic resistance. Phagos reports about 50 employees across microbiology and AI, 11 clinical trials of AI-powered phage treatments, and roughly one million animals treated in the field.